Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania

Journal of Psychopharmacology

Volumn 25, Issue 2, 2011, Pages 274-279

  Valvassori, Samira S ^a,e   Elias, Guilherme ^a,e   De Souza, Bruna ^a,e   Petronilho, Fabrícia ^a,e   Dal Pizzol, Felipe ^a,e   Kapczinski, Flávio ^b,e   Trzesniak, Clarissa ^c,e   Tumas, Vitor ^c,e   Dursun, Serdar ^d,e   Nisihara Chagas, Marcos Hortes ^c,e   Hallak, Jaime Ec ^c,e   Zuardi, Antonio W ^c,e   Quevedo, João ^a,e   Crippa, José As ^c,e  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF ALBERTA   (Canada)

^e National Science and Technology Institute INCT for Translational Medicine   (Brazil)

Author keywords

BDNF; bipolar disorder; cannabidiol; mania; oxidative stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CARBONYL DERIVATIVE; DEXAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; DRUG EFFECT; HIPPOCAMPUS; LOCOMOTION; MALE; MANIA; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; HYPERKINESIS; MALE; MOTOR ACTIVITY; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN CARBONYLATION; RATS; RATS, WISTAR;

EID: 79551657250     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106925     Document Type: Article

References (42)

1. Andreazza AC, Kauer-Santanna M., Frey BN, et al. (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111: 135-144.
2. Ashton H., Young AH (2003) GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 17: 174-178.
3. Bhattacharyya S., Crippa JA, Martin-Santos R., Winton-Brown T., Fusar-Poli P. (2009) Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des in press.
4. Borgwardt SJ, Allen P., Bhattacharyya S., et al. (2008) Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966-973.
5. Carlini EA, Leite JR, Tanhauser M., Berardi AC (1973) Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25: 664-665.
6. Cheng HY, Hsieh MT, Wu CR, et al. (2008) Schizandrin protects primary cultures of rat cortical cells from glutamate-induced excitotoxicity. J Pharmacol Sci 107: 21-31.
7. Crippa JA, Zuardi AW, Garrido GE, et al. (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417-426.
8. Cunha JM, Carlini EA, Pereira AE, et al. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185.
9. Esposito G., De Filippis D., Carnuccio R., Izzo AA, Iuvone T. (2006 a) The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/betacatenin pathway rescue in PC12 cells. J Mol Med 84: 253-258.
10. Esposito G., De Filippis D., Maiuri MC, De Stefano D., Carnuccio R., Iuvone T. (2006 b) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399: 91-95.
11. Esposito G., Scuderi C., Savani C., et al. (2007) Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151: 1272-1279.
12. Frey BN, Andreazza AC, Ceresér KM, et al. (2006 a) Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79: 281-286.
13. Frey BN, Valvassori SS, Réus GZ, et al. (2006 b) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31: 326-332.
14. Fusar-Poli P., Crippa JA, Bhattacharyya S., et al. (2009) Neurofunctional modulation of emotional processing by ?9-tetrahydrocannabinol and cannabidiol. Arch Gen Psychiatry 66: 95-105.
15. Garcia-Arencibia M., Gonzalez S., de Lago E., Ramos JA, Mechoulam R., Fernandez-Ruiz J. (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinsons disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134: 162-170.
16. Goodwin FK (2003) Impact of formularies on clinical innovation. J Clin Psychiatry 64 (Suppl 5). 18-24.
17. Guimarães FS, Chiaretti TM, Graeff F., Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100: 558-559.
18. Guimarães VM, Zuardi AW, Del Bel EA, Guimarães FS (2004) Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sciences 75: 633-638.
19. Hamelink C., Hampson A., Wink DA, Eiden LE, Eskay RL (2005) Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 314: 780-788.
20. Hampson AJ, Grimaldi M., Axelrod, Wink D (1998) Cannabidiol and delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268-8273.
21. Hermann D., Sartorius A., Welzel H., et al. (2007) Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 61: 1281-1289.
22. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., Izzo AA (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89: 134-141.
23. Izquierdo I., Orsingher OA, Berardi AC (1973) Effect of cannabidiol and other Cannabis sativa compounds on hippocampal seizures discharges. Psychopharmacologia 28: 95-102.
24. Kuhlmann CR, Gerigk M., Bender B., Closhen D., Lessmann V., Luhmann HJ (2008) Fluvastatin prevents glutamate-induced blood-brain-barrier disruption in vitro. Life Sci 8: 1281-1287.
25. Lastres-Becker I., Molina-Holgado F., Ramos JA, Mechoulam R., Fernandez-Ruiz J. (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinsons disease. Neurobiol Dis 19: 96-107.
26. Machado-Vieira R., Andreazza AC, Viale CI, et al. (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421: 33-36.
27. Mitchell PB, Malhi GS (2006) Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs 11: 621-634.
28. Monti JM (1977) Hypnotic-like effects of cannabidiol in the rat. Psychopharmacol (Berl) 55: 263-265.
29. Moreira FA, Aguiar DC, Guimarães FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30: 1466-1471.
30. Musty RE, Bouldin MJ, Erickson JR, Deyo R. (2002) CBD and THC extracts alter Behavioral Despair on the Mouse Tail Suspension Test. Asilomar Conference Center. 2002 Symposium on the Cannabinoids, Burlington, VT. International Cannabinoid Research Society, p. 140.
31. Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009.
32. Porter R., Ferrier N., Ashton H. (1999) Anticonvulsants as mood stabilisers. Adv Psychiatr Treat 5: 96-103.
33. Sagredo O., Ramos JA, Decio A., Mechoulam R., Fernández-Ruiz J. (2007) Cannabidiol reduced the striatal atrophy caused 3-nitro-propionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26: 843-851.
34. Turkanis SA, Cely W., Olsen DM, Karler R. (1974) Anticonvulsant properties of cannabidiol. Res Communic Chem Pathol Pharmacol 8: 231-246.
35. Zuardi AW (2006) History of cannabis as a medicine: a review. Rev Bras Psiquiatr 28: 153-157.
36. Zuardi AW, Cosme RA, Graeff FG, et al. (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88.
37. Zuardi AW, Crippa JAS, Dursun SM, et al. (2008 a) Cannabidiol was not effective for manic episode of bipolar affective disorder. J Psychopharmacol doi:10.1177/0269881108096521, in press.
38. Zuardi AW, Crippa JAS, Hallak JEC, et al. (2008 b) Cannabidiol for the treatment of psychosis in Parkinsons disease. J Psychopharmacology 23: 979-983.
39. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS (2006 a) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.
40. Zuardi AW, Hallak JE, Dursun SM, et al. (2006 b) Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20: 683-686.
41. Zuardi AW, Karniol IG (1983) Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16: 141-146.
42. Zuardi AW, Shirakawa I., Finkelfarb E., Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76: 245-250.